1	RT-RPA-Cas12a-based discrimination of SARS-CoV-2 variants of
2	concern
3	
4	Guiyue Tang ^{1,#} , Zilong Zhang ^{2,#} , Wei Tan ^{1,#} , Fei Long ¹ , Jingxian Sun ¹ , Yingying Li ¹ ,
5	Siwei Zou ¹ , Yujiao Yang ^{3,4} , Kezhu Cai ^{1,5} , Shenwei Li ² , Zhiyi Wang ² , Jiakun Liu ¹ ,
6	Guobing Mao ¹ , Yingxin Ma ¹ , Guo-Ping Zhao ^{1,3,4,6,*} , Zhen-Gan Tian ^{2,*} , Wei Zhao ^{1,*}
7	
8	¹ CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of
9	Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy
10	of Sciences, Shenzhen 518055, China;
11	² Shanghai International Travel Healthcare Center, Shanghai Customs District P. R.
12	China, Shanghai 200335, China;
13	³ CAS Key Laboratory of Synthetic Biology, CAS Center for Excellence in
14	Molecular Plant Sciences, Chinese Academy of Sciences, Shanghai 200032, China;
15	⁴ CAS Key Laboratory of Synthetic Biology, University of Chinese Academy of
16	Sciences, Beijing 100049, China;
17	⁵ School of Engineering, Southern University of Science and Technology, Shenzhen
18	518055, China;
19	⁶ State Key Lab of Genetic Engineering & Institutes of Biomedical Sciences,
20	Department of Microbiology and Microbial Engineering, School of Life Sciences,
21	Fudan University, Shanghai 200433, China;
22	
23	[#] These authors contributed equally.
24	*To whom correspondence should be addressed: wei.zhao1@siat.ac.cn,
25 NC	tianzhenganciq@163.com, and gpzhao@sibs.ac.cn. DTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Abstract

27	Timely and accurate detection of SARS-CoV-2 variants of concern (VOCs) is
28	urgently needed for pandemic surveillance and control. However, current methods are
29	limited by the low sensitivity, long turn-around time or high cost. Here, we report a
30	nucleic acid testing-based method aiming to detect and discriminate SARS-CoV-2
31	VOCs by combining <u>RT-RPA</u> and <u>CRISPR-Cas12a</u> detecting assays (RRCd). With a
32	detection limit of 10 copies RNA/reaction, RRCd was validated in 204 clinical
33	samples, showing 99% positive predictive agreement and 100% negative predictive
34	agreement, respectively. Critically, using specific crRNAs, representatives of single
35	nucleotide polymorphisms and small deletions in SARS-CoV-2 VOCs including
36	N501Y, T478K and Δ H69-V70 were discriminated by RRCd, demonstrating 100%
37	accuracy in clinical samples with $C_t < 33$. The method completes within 65 min and
38	could offer visible results without using any electrical devices, which may facilitate
39	point-of-care testing of SARS-CoV-2 and its variants.
40	

41 Keywords

42 SARS-CoV-2, variant of concern, RRCd, point-of-care testing, CRISPR

43 Introduction

44	The pandemic of COVID-19 has caused 494.5 million infections and 6.1 million
45	deaths as of April 10th 2022 (https://covid19.who.int/table). The pathogen of this
46	pandemic, SARS-CoV-2, has undergone rapid and constant mutations in the process
47	of transmissions, bringing worldwide uncertainty to the diagnostics, vaccine
48	effectiveness and therapeutics (Tao et al. 2021).
49	Since November 2020, generally five rapidly expanding SARS-CoV-2 lineages
50	have been discovered and designated as variants of concern (VOCs), <i>i.e.</i> , the Alpha,
51	Beta, Gamma, Delta, and Omicron (Oude Munnink et al. 2021) (Supplementary
52	Figure 1). Besides the current Omicron, among these lineages, the Alpha and Delta
53	VOCs were dominant in frequency over a relatively long period of time. With gradual
54	resumption of air travel, Customs, and ports, certain previously isolated areas were
55	riskily exposed to the SARS-CoV-2 variants. These variants, either with higher
56	infectivity or increased pathogenicity, could trigger multiple outbreak waves unless
57	they are detected timely and accurately (Tao et al. 2021, Oude Munnink et al. 2021).
58	Although quantitative reverse transcription PCR (RT-qPCR) performs as a gold
59	standard for the SARS-CoV-2 detection, it is barely used to genotype the
60	SARS-CoV-2 VOCs due to the limitations as an amplicon-based method. The current
61	method is heavily based on in-depth whole-genome sequencing, which not only relies
62	on bulk instruments and trained personnel but is also time-consuming and with
63	relatively high cost (Crits-Christoph et al. 2021, Kumar et al. 2021). A recent study
64	showed that the multiplex qPCR could discriminate some SARS-CoV-2 VOCs by
65	targeting specific small deletions(Vogels et al. 2021). However, this method is
66	insensitive to the key point mutations and other developing variations in
67	SARS-CoV-2. Similarly, antigen-based detection assays have lower sensitivity than

RT-qPCR and have not yet been reported to identify SARS-CoV-2 VOCs (Peto and
Team 2021).

70	CRISPR-based technology was proven to have unique advantages in molecular
71	diagnosis over the conventional PCR methods in terms of specificity and operability
72	(Chen et al. 2018, Joung et al. 2020, Fozouni et al. 2021). Two CRISPR-based
73	COVID-19 diagnostic methods, DETECTR and SHERLOCK, have been developed
74	using either Cas12a or Cas13a, with the characteristics of rapid, ultrasensitive and
75	easy-to-implement (Broughton et al. 2020, Patchsung et al. 2020). Moreover, CRISPR
76	assays such as RAY were employed to identify the point mutations in SARS-CoV-2
77	due to the high specificity of Cas/guide-RNA recognition (Kumar et al. 2021, Wang et
78	al. 2021). Nevertheless, the relying on well-designed ligation probes somehow limited
79	the targeting capability to diverse mutation sites. Recently, CRISPR-based
80	point-of-care tests (POCT) of SARS-CoV-2 were reported (de Puig et al. 2021, Teng
81	et al. 2019). The methods provided visual readout using minimal fluorescent
82	instruments and could identify multiple SARS-CoV-2 VOCs, among the synthetic
83	samples though. Hence, significant efforts are still needed in respect to improving the
84	detection sensitivity and validating the methods with clinical samples.
85	Here, we report a method combining reverse transcription-recombinase
86	polymerase amplification (RT-RPA) and CRISPR-Cas12a technology based on our
87	HOLMES test platform (Li, Cheng, Liu, et al. 2018, Li, Cheng, Wang, et al. 2018),
88	aiming to detect and discriminate SARS-CoV-2 VOCs. By exchanging the crRNA
89	sequences, the method (RRCd) achieved to discriminate the well-known single
90	nucleotide polymorphisms (SNPs) of N501Y and T478K as well as the small deletion
91	of Δ H69-V70, corresponding to the major VOCs worldwide. RRCd was validated in
92	204 clinical samples after being systematic optimization, showing 99% positive

93 predictive agreement and 100% negative predictive agreement, respectively. The results of RRCd could be visualized within about one hour. Moreover, all procedures 94 including the sample lysis were able to carry out at 37 °C and with no needs for RNA 95 extraction and purification, which is very conducive to the development of POCT 96 products. 97 98 Results 99 **Technical route of RRCd assay** 100 101 The CRISPR-LbCas12a-based nucleic acid test platform HOLMES (Li, Cheng, Wang, et al. 2018) was chosen as the starting core to design the technical route for 102 103 RRCd (Figure 1, Supplementary Figure 2). We conduct a two-step RT-RPA 104 amplification on SARS-CoV-2 genes to provide adequate double-stranded DNA (dsDNA) for the following CRISPR recognition system (Figure 1, II). By designing 105 specific crRNA, Cas12a recognizes and *cis*-cleaves the dsDNA templates of 106 107 SARS-CoV-2 or its variants. Meanwhile, the formation of the ternary complex of Cas12a-crRNA-dsDNA activates the *trans*-activity of Cas12a, which leads to the 108 cleavage of the non-targeted single-stranded DNA (ssDNA) probe in the system 109 (Figure 1, III). The results could be quantified directly by fluorescence detection of 110 111 the fluorophore-quencher ssDNA (FQ-ssDNA) (Figure 1, IIIa) or captured by 112 lateral-flow strip using the FITC-Biotin ssDNA (FB-ssDNA) (Figure 1, IIIb). Hence, different from the previous methods (Broughton et al. 2020, Patchsung 113 et al. 2020, Ding et al. 2020), RRCd combines the advantages of high sensitivity of 114 115 RT-RPA (Lobato and O'Sullivan 2018) and high specificity of CRISPR-Cas12a (Chen et al. 2018) (Table 1). In comparison with Cas9 and Cas13, Cas12a in RRCd 116

117 possesses greater specificity and lower mismatch tolerance (Chen et al. 2018), making

118 it more suitable for SARS-CoV-2 VOCs genotyping.

119

120 The specificity analyses of RRCd assay

121 Representative mutations in spike (S) protein were used for genotyping of the

122 SARS-CoV-2 lineages (Munnink et al. 2021) (Figure 2A). By screening optimal

123 RT-RPA primers (Supplementary Figure 3) and crRNAs (Supplementary Figure 4)

124 that target to the S protein encoding gene, RRCd was readily applied for the detection

and discrimination of SARS-CoV-2 VOCs (Figure 2B-G). These VOCs include the

126 first reported Alpha and Beta mutation N501Y (Tegally et al. 2021) (Figure 2B, C),

127 the recent reported T478K mutation in Delta and Omicron VOCs (Kumar et al. 2022)

128 (Figure 2D, E), and the small deletions such as Δ H69-V70 in Alpha and Omicron

129 VOCs (Meng et al. 2021) (Figure 2F, G). The N501Y mutation in the

130 receptor-binding domain (RBD) of S protein was reported to cause an increased

131 transmission and infectivity of SARS-CoV-2 (Liu et al. 2022). The T478K nutation in

the RBD is also involved in higher transmissibility by the increased affinity to human

ACE2 receptor (Kumar et al. 2022), while the deletion of H69V70 at the N-terminal

134 domain is shown to allow the virus to replicate more efficiently (Meng et al. 2021).

135 Our test results were demonstrated by both the fluorescence-based and

136 lateral-flow readouts, representing the *trans*-cleavage activity of Cas12a (Chen et al.

137 2018, Li, Cheng, Liu, et al. 2018) (Figure 2B-G). Additionally, we confirmed this

138 specific cleavage using polyacrylamide gel electrophoresis analyses by leveraging of

139 the Cas12a cis-cleavage activity (Chen et al. 2018) (Figure 2H-J). Moreover, RRCd

140 can be used for the discrimination of SARS-CoV-2 from other phylogenetic related

141 viruses (Supplementary Figure 5).

142

143 The detection limit of RRCd

To determine the limit of detection (LoD) of RRCd, we built a standard curve to 144 dissect the correspondences between the viral copy numbers and the C_t values using 145 SARS-CoV-2 pseudovirus (Supplementary Figure 6). The Ct values of each dilution 146 were measured using RT-qPCR targeting N gene or ORF1ab gene to mimic the 147 clinical C_t ranges. Despite showing distinct kinetics, the fluorescence-based readouts 148 revealed that the LoDs of all the targeted regions (E gene, N501, Y501, T478, and 149 150 K478 of S gene) were ~10 copies per reactions, corresponding to a C_t value of 35 in the RT-qPCR assay (Figure 3). The fluorescence results from a 30-min CRISPR 151 reaction suggested that the detection sensitivity of N501 is a slightly higher than that 152 153 of Y501 (Figure 3B, C), while the detection sensitivity of T478 is a slightly lower than that of K478 (Figure 3D, E). It is worth noting that the detection sensitivity of 154 the lateral-flow readouts is about 10-folds lower than that of the fluorescence-based 155 readouts (Figure 3). The detection of Y501 and K478 was shown to be the most 156 sensitive when using the lateral-flow readout, with the LoDs of ~10 copies per 157 reactions (Figure 3C, E). 158 To avoid false-discriminative results, we further assessed the factors that may 159 affect the detection sensitivity in RRCd, including the sample volume and probe 160 161 inputs, the usage of RNase H, T4 gene 32 protein, Bsu DNA polymerase, RPA kits,

and Mg²⁺. We found the sample volume and the usage of T4 gene 32 protein (Villalva
et al. 2001) are the key factors affecting RRCd sensitivity mostly (Supplementary

164 **Figure 7**).

165

166

167 Validation of RRCd in detection and discrimination of clinical samples

Based on the optimized procedures, we evaluated the performance of RRCd on detecting COVID-19 clinical samples isolated from nasopharyngeal and salivary swabs. In coordination with the scenario of POCT, our available samples were collected from Shanghai Customs where the susceptible patients were characterized as asymptomatic and with low virus load (**Supplementary Figure 8**). To minimize the cognitive bias, all information of the clinical samples was confidential to study staff before the detection.

175 A validation study of SARS-CoV-2 detection was conducted on a total of 96 clinical samples (54 RT-qPCR-verified positive samples and 42 RT-qPCR-verified 176 negative samples). Both E gene and S gene were used as the targeted sequences to 177 178 acquire the double-checked detection results (Figure 4, Supplementary Figure 9). RRCd identified all the positive samples with $C_t < 33$ through both lateral-flow and 179 fluorescence-based readouts. In addition, 42 COVID-19 negative samples were all 180 181 identified without false positive results from both readouts. Samples beyond the $C_{\rm t}$ value of 32 were more likely to be detected by targeting the E gene ($C_t \le 35, 100\%$ 182 detected) than the S gene (Figure 4). The detection sensitivity of these results was 183 comparable to the RT-LAMP-Cas12 based DETECTR (Broughton et al. 2020) and 184 185 the RT-RPA-Cas13 based SHERLOCK (Patchsung et al. 2020), showing a 99% 186 positive predictive agreement (PPA) and 100% negative predictive agreement (NPA) in both readouts ($C_t < 33$) (Table 2). 187 We next evaluated the performance of RRCd on discrimination of SARS-CoV-2 188 189 VOCs. The 501 position of S gene was used as a target to detect SARS-CoV-2 VOCs,

190 such as the Alpha, Beta, Gamma, and Omicron (Tegally et al. 2021). A total of 68

191 clinical samples, consisting of 28 genome-sequencing-verified N501 samples and 19

192	genome-sequencing-verified Y501 samples, were collected from March 3 rd to April
193	10th 2021 at Shanghai Customs. RRCd discriminated all the variants from samples
194	with a $C_t < 32$, either using lateral-flow readouts or fluorescence-based readouts
195	(Figure 5A, Supplementary Figure 10). However, the discrimination ability
196	decreased strikingly when testing the samples with C_t values beyond 33, which is
197	possibly due to the relatively high LoD of S gene 501 as mentioned above (Figure 3).
198	The 478 position of S gene could be used as a target to identify Delta and
199	Omicron VOCs (Figure 5B, Supplementary Figure 11). A total of 40 clinical
200	positive samples, consisting of 7 genome-sequencing-verified T478 samples and 14
201	genome-sequencing-verified K478 samples, were collected from May 27th and
202	October 29 th 2021. RRCd was able to discriminate all the variants targeting the S gene
203	478. Moreover, RRCd displayed a relatively higher sensitivity in detecting the
204	position of 478 than that of 501, with the C_t value reaching 34. Although using a
205	relatively small sample group, the detection results were confirmed by both readouts
206	with 0% false-discriminant rates (Figure 5B). Taken together, these clinical data
207	suggested that RRCd was able to detect and discriminate the SARS-CoV-2 VOCs,
208	accurately and sensitively (Table 2).

209

210 Discussion

Although a decreased lethality of the circulating Omicron has been reported, its overall mortality rate has not dropped because its dramatically increased infectivity (Nyberg et al. 2022). The frequent outbreak waves of COVID-19 highlight the needs for detection methods that are rapid, sensitive, and specific. However, the current method relying on deep genome sequencing is limited by the high cost, long turn-around time, and the reduced overall sensitivity (Kumar et al. 2021). Although

217	the recently developed CRISPR-based methods were characterized as sensitive and
218	easy-to-implement, most of them were barely validated by the large clinical samples
219	or have a limited adaptability (Wang et al. 2021, Teng et al. 2019, de Puig et al. 2021).
220	In the present study, RRCd completed in \sim 1 hour and displayed a sensitivity
221	down to 10 copies per reaction. By targeting and identifying the representative N501Y,
222	T478K and Δ H69-V70 mutations, RRCd discriminated COVID-19 samples of Alpha,
223	Delta, and Omicron VOCs. The method was validated in 204 clinical COVID-19
224	samples, with 99% PPA and 100% NPA for the samples of $C_t < 33$ through both the
225	fluorescence and the lateral-flow readouts (Table 2). Moreover, The SARS-CoV-2
226	detection by direct lysing the clinic samples without RNA extraction and purification
227	was demonstrated (Supplementary Figure 12). Although a relatively small sample
228	size was used, these results indicated that the whole process of RRCd including the
229	RT-RPA amplification and the lateral-flow detection is independent of electrical
230	devices, which may facilitate the development of POCT products (Table 1).
231	In addition, the RRCd assay has the potential to be easily adapted to detect
232	novel mutations on SARS-CoV-2 or other viruses by designing the new RT-RPA
233	primers and crRNAs, without changing the subsequent detection procedures and
234	ssDNA probes (Figure 1, Supplementary Figure 2). Overall, RRCd can be
235	performed in sites with few detection equipment (e.g., self-testing) or limited power
236	access (e.g., underdeveloped areas), or situations when quick turnaround times are
237	needed (e.g., hospital emergency). Nevertheless, the POCT products for RRCd needs
238	to be further investigated.

239

240 Materials and methods

241 Clinical sample collection and ethics statement

- All 204 nasopharyngeal and salivary samples were collected at Shanghai 242 International Travel Healthcare Center (SITHC), Shanghai Customs District P. R. 243 China, from March 3rd and to October 29th 2021. The samples were treated in strict 244 accordance with WHO recommended standard operation procedure. Ethical approval 245 246 of the study was given by the Bioethics Committee of Bio-X Institute of Shanghai Jiao Tong University (COA: M202007). 247 248 **RT-qPCR** for the SARS-CoV-2 detection 249 The viral RNA of each swab was extracted and purified from a 200 µl-swab 250 251 transport media using an automatic nucleic acid platform (SSNP-3000A, Bioperfectus tech., China) according to the manufacturer's instruction. A 100 µl 252 RNase-free water was used to elute the RNA. Viral lysis and RNA extraction were 253 performed in a biosafety level 3 laboratory, whereas other procedures were 254 255 performed in a biosafety level 2 laboratory. The quantitative reverse transcription PCR (RT-qPCR) for SARS-CoV-2 256 detection was performed with a 2019-nCoV nucleic acid detection kit (BioGerm, 257 Shanghai, China) according to the manufacturer's protocol. Each RT-qPCR reaction 258 259 had a final volume of 25 μ l, including 5 μ l purified RNA, 12 μ l reaction buffer, 4 μ l enzyme solution and 4 µl probe primers solution. RT-qPCR assay was performed on 260 QuantStudio Dx Real-Time PCR (Applied Biosystems, MA, USA) under the 261
- following conditions: incubation at 50 °C for 15 min and 95 °C for 5 min, 45 cycles
- 263 of denaturation at 94 °C for 15 s, and extension and fluorescence signal reading at
- 264 55 °C for 45 s. Two target genes, *i.e.*, the *ORF1ab* gene and the *N* gene, were

- simultaneously amplified and tested in the RT-qPCR assay. The test result was
- deemed as positive when the cycle threshold values (C_t value) of both
- 267 *ORF1ab* and *N* genes \leq 38; otherwise, a negative result was deemed. These
- 268 diagnostic criteria were based on the recommendation from the National Institute for
- 269 Viral Disease Control and Prevention (China)
- 270 (http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html).
- 271

272 Design and screening of the RT-RPA primers and crRNAs

For the detection of SARS-CoV-2, *E* gene was selected as the test target using

the RT-RPA primers and crRNA recommended by WHO with minor modifications

275 (Supplementary Table 1).

276 For the detection of SARS-CoV-2 VOCs, the representative mutations in the S gene were selected as the test targets. Aiming to distinguish the most prevailing 277 SARS-CoV-2 VOCs (i.e., the Alpha, Delta, and Omicron), we designed the RT-RPA 278 primers on the conserved regions flanking the mutations of S gene 478 and 501 279 (Supplementary Table 1), respectively, and screened the best pairs by agarose gel 280 analyses for the amplification efficiency of dsDNA. Two pairs of optimal RT-RPA 281 primers (S501RPAF1/S501RPAR1 and S478RPAF3/S478RPAR5) were selected for 282 the detection of S gene 478 and 501, respectively. To further evaluate their 283 284 applicability in the detection of clinical samples, these RT-RPA primers were aligned with 859,132 full-length SARS-CoV-2 genome sequences collected from January 1st 285 2021 to December 31th 2021 in the GISAID database (Buch et al. 2011). The results 286 287 showed that these pairs of RT-RPA primers hit 99.7% of the genome sequences, demonstrating a good applicability in detection of prevailing clinical samples. 288 Optimal crRNAs for the discrimination of S gene 501 variants were assessed 289

290	by determining the specificity of the crRNA to the single-base mismatched S gene
291	templates. DNA fragments containing wild-type S gene 501 with point mutations
292	were synthesized in pUC19 backbone plasmid by Sangon Biotech. These S gene 501
293	regions were transcribed into RNA using HiScribe T7 High Yield RNA Synthesis kit
294	(Cat# E2050S, New England Biolabs) at 37 °C for 4 h, whose products were further
295	analyzed using both fluorescence-based and lateral-flow readouts. The crRNA-N501
296	was employed to discriminate the single-base mismatches. Based on this approach,
297	we designed the crRNAs for the discrimination of other SARS-CoV-2 VOCs. All
298	crRNA and RT-RPA primer sequences used in this study are listed in
299	Supplementary Table 1.
300	
301	crRNA generation
302	The DNA templates (Supplementary Table 1) for in vitro transcription (IVT)
303	of crRNAs were designed with T7 primer binding sites using CRISPR-RT Design
304	Tool (http://bioinfolab.miamioh.edu/CRISPR-RT) and synthesized by Sangon
305	Biotech (Shanghai, China). The crRNAs were transcribed using HiScribe T7 High
306	Yield RNA Synthesis kit (Cat [#] E2050S, New England Biolabs) at 37 °C for 16 h.
307	Then, the crRNAs were purified using RNA Clean and Concentrator kit (Cat# R1017,
308	Zymo Research). The concentration of crRNA was quantified by NanoDrop 2000C
309	spectrophotometer (Thermo Scientific) and stored at -80 °C before use.
310	Reverse transcription and recombinase polymerase amplification (RT-RPA)
311	A 20 μ l volume-basic RT reaction mixture was used with 1 × RT buffer (Cat [#]

EP0442, Thermo Scientific), 10 μl RNA template, 200 U RevertAid reverse

313 transcriptase (Cat[#] EP0442, Thermo Scientific), 1.25 μ M RT-RPA forward and

314	reverse primer mix, 1 mM dNTP mix (Cat# P031-01, Vazyme, Nanjing, China), and
315	20 U RNase inhibitor (Cat# N8080119, Thermo Scientific). The RT reaction mixture
316	was incubated at 37 °C for 15 min to generate cDNA. Then, a 10 μ l RT product was
317	transferred into the 50 μ l-basic RPA reaction mixture, which contains 29.5 μ l
318	rehydration buffer, one freeze-dried RPA reaction pellet (Cat# TABAS03KIT,
319	TwistDx), 0.5 μ M RT-RPA forward and reverse primer mix, and 14 mM MgOAc
320	(last added to initiate the reaction). The RPA reaction mixture was incubated at 37 $^{\circ}$ C
321	for another 15 min. The RNA extracts from SARS-CoV-2 pseudovirus and the
322	RNase-free water were used as the positive control (PC) and negative control (NC),
323	respectively.
324	
325	CRISPR trans-cleavage assay for fluorescence-based and lateral-flow readouts
326	Briefly, a 100 μl volume basic CRISPR reaction mixture was used with 1 \times
327	<i>Lba</i> Cas12a buffer, 5 μl RT-RPA product, 0.2 μM <i>Lba</i> Cas12a (Cat [#] M0653T, New
328	England Biolabs), 0.6 µM crRNA, 10 µM MgCl ₂ , 10 nM fluorophore
329	(FAM)-quencher (BHQ1) ssDNA probe (FQ-ssDNA, Sangon Biotech) for the
330	fluorescence-based detection, or 50 nM FTIC-Biotin ssDNA probe (FB-ssDNA,
331	Zoonbio Biotechnology, Nanjing, China) for the lateral flow-based detection.
332	For the fluorescence-based readout, a 96-well plate containing 100 µl reaction
333	
	mixture was incubated at 37 °C using the Cytation 5 Mul-Mode Reader (BioTek, VT,
334	mixture was incubated at 37 °C using the Cytation 5 Mul-Mode Reader (BioTek, VT, USA). Usually, a 60-min monitoring was used with an interval time of 30 s. The
334 335	mixture was incubated at 37 °C using the Cytation 5 Mul-Mode Reader (BioTek, VT, USA). Usually, a 60-min monitoring was used with an interval time of 30 s. The fluorescence excitation and emission wavelength were set as 485 nm and 520 nm,
334335336	mixture was incubated at 37 °C using the Cytation 5 Mul-Mode Reader (BioTek, VT, USA). Usually, a 60-min monitoring was used with an interval time of 30 s. The fluorescence excitation and emission wavelength were set as 485 nm and 520 nm, respectively. The relative fluorescence intensity (F/F ₀) was calculated as the
334335336337	 mixture was incubated at 37 °C using the Cytation 5 Mul-Mode Reader (BioTek, VT, USA). Usually, a 60-min monitoring was used with an interval time of 30 s. The fluorescence excitation and emission wavelength were set as 485 nm and 520 nm, respectively. The relative fluorescence intensity (F/F₀) was calculated as the fluorescence signal relative to the starting signal. Generally, the fluorescence signals

339 $(F_{30}/F_0)_{NC} \ge 1.2$ indicates the positive result while $(F_{30}/F_0)_{Sample} / (F_{30}/F_0)_{NC} < 1.2$

340 indicates the negative result.

341	For the lateral flow readout, a 100 μ l-reaction mixture was incubated in an
342	Eppendorf tube at 37 °C for 30 min. Then, the HybriDetect strip (Milenia Biotec,
343	Giessen, Germany) was placed into the Eppendorf tube, and the C-line and/or T-line
344	were visualized and stabilized in ~2 min. The relative greyness of the T-line (G) was
345	quantified using ImageJ. In this study, $G_{Sample}/G_{NC}{\geq}1.5$ indicates the positive result
346	while $G_{\text{Sample}} / G_{\text{NC}} < 1.5$ indicates the negative result. Due to the incomplete
347	digestion of FB-ssDNA, some positive test results displayed two lines (T-line and
348	C-line) on the strips.
349	
350	CRISPR cis-cleavage assay
351	Upon detection of the targeted sites, the CRISPR-Cas12a system is capable to
352	cis-cleave the dsDNA template into two short fragments, the activity of which was
353	determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
354	(SDS-PAGE). After a 30-min incubation of the CRISPR reaction mixture as
355	described above, the mixture was denatured at 95 °C for 5 min. Then, it was loaded
356	into an 8% SDS-PAGE for 45 min at 150 V. The gel was stained with GelRed
357	(Biotium, CA, USA) and analyzed by Image J.
358	
359	Specificity of RRCd assay
360	To test if RRCd could discriminate SARS-CoV-2 from the phylogenetically
361	related viruses, DNA fragments containing selected regions of N gene of SARS-CoV
362	(NC_004718.3), MERS CoV (NC_019843.3), and H1N1 (NC_026433.1,
363	NC_026434.1) were synthesized from Sangon Biotech (Supplementary Table 2),

364	and then	cloned	into a	T7	nromoter	expression	nlasmid	to	he u	sed a	s the	temr	lates	for
50-	and then	cioneu	mo a	/ 1 /	promotor	CAPICSSION	prasinnu	ω	uc u	scu a	suic	uni	Jacos	101

- 365 IVT of viral RNAs, respectively. The transcribed RNAs were detected using
- 366 crRNA-SARS-CoV2 *N* by the RRCd assay as described above.
- 367
- 368 Building a standard curve to determine the relationship between viral copy
- 369 **numbers and the** *C***t values**
- 370 The pseudovirus SARS-CoV-2 ab II EMNS S-MT and
- 371 SARS-CoV-2-MT-B.1.617.2. (Supplementary Table 3) were purchased from
- 372 FUBIO, Nanjing, China. To establish the correlation between viral copy numbers
- and the C_t values of SARS-CoV-2, we built a standard curve using a gradient

dilution $(1 \times 10^5, 1 \times 10^4, 1 \times 10^3, 1 \times 10^2, 10 \text{ and } 5 \text{ RNA copies per reaction})$ of

375 SARS-CoV-2 ab II EMNS S-MT. The C_t values of the samples were determined by

targeting N gene and ORF1ab gene with RT-qPCR as mentioned above. Results were

377 plotted against the viral copy numbers yielding a linear relationship.

378

379 Limit of detection (LoD) of RRCd assay

To determinate the detection limits of RRCd assay for different SARS-CoV-2 380 variants (E gene, T478, K478, N501 and Y501 in S gene), nine serial dilutions (1 \times 381 10^7 , 1×10^6 , 1×10^5 , 1×10^4 , 1×10^3 , 1×10^2 , 10 and 5 copies per reaction) of 382 383 SARS-CoV-2 pseudovirus RNAs were used and their fluorescence-based and lateral-flow readouts were analyzed as described above. For the dilutions $(1 \times 10^7, 1)$ 384 $\times 10^6$, 1×10^5 , 1×10^4 , 1×10^3 and 1×10^2 copies per reaction), at least three 385 386 independent experiments were performed, while for the dilutions with 10 and 5 copies per reaction, at least five independent experiments were conducted. 387 RNase-free water was used as the negative control. 388

389

390 Whole-genome sequencing of clinical samples

- 391 To determine the lineages of the RT-qPCR-verified positive clinical samples,
- 392 whole-genome sequencing of SARS-CoV-2 cDNA was conducted by Illumina
- 393 Next-generation sequencing. The first-strand cDNA of SARS-CoV-2 RNA was
- 394 generated using the SuperScript IV First-Strand Synthesis System (Cat[#] 18091050,
- 395 Thermo Fisher Scientific). The corresponding libraries were constructed using the
- 396 cDNAs with the ARTIC SARS-CoV-2 amplification protocol (as described in
- 397 https://artic.network/ncov-2019). Paired-end 150 bp sequencing was performed for
- each library on Illumina X-10. Genome assembly was done using CLC Genomics
- 399 Workbench (<u>http://www.clcbio.com/products/clcgenomics-workbench/</u>) (Liu and Di
- 400 2020). The Phylogenetic Assignment of Named Global Outbreak Lineages
- 401 (PANGOLIN) (https://virological.org/t/pangolin-web-application-release/482) (Lam
- 402 et al. 2020) and the NextClade (https://clades.nextstrain.org/) (Hadfield et al. 2018)
- 403 were used for lineage classification and clade classification, respectively. All the S
- 404 gene from the positive clinical samples used in this study were re-sequenced by

405 Sanger method.

406

407 **Optimization of RRCd assay**

To optimize the RT reaction, we first investigated the effects of different RNA input (1, 5, or 10 μ l) on the detection sensitivity of RRCd. RNA was extracted from a positive clinical sample (C_t = 30) as described above and the SARS-CoV-2 *E* gene was used as the test target.

412 RNase H is an endoribonuclease that specifically hydrolyzes the RNA-DNA
413 hybrids(Qian et al. 2020), while T4 gene 32 protein is known to increase the

414 efficiency of reverse transcriptase(Villalva et al. 2001) and Bsu DNA polymerase has the strand displacement DNA synthesis activity(Piepenburg et al. 2006). To evaluate 415 the effects of these enzymes on RT-RPA efficiency, a basic RT reaction mixture was 416 prepared as described above with or without the addition of 250 U RNase H (Cat[#] 417 M0297S, New England Biolabs), 16.5 µM T4 gene 32 protein (Cat[#] M0300L, New 418 England Biolabs) or 0.25 U Bsu DNA polymerase (Cat[#] M0330S, New England 419 420 Biolabs), respectively. The corresponding RT products were used as inputs to the RPA assay and 421 422 subsequent products were analyzed by fluorescence based CRISPR assay as described above. Finally, a 20 µl volume-optimized RT reaction mixture was 423 obtained as below: 1 × RT buffer, 10 µl template RNA, 200 U RevertAid reverse 424 425 transcriptase (Thermo Scientific), 1.25 µM RT-RPA forward and reverse primer mix, 1 mM dNTP mix, 20 U RNase inhibitor (Thermo Scientific), 250 U RNase H (New 426 England Biolabs) and 16.5 µM T4 gene 32 protein (New England Biolabs). 427 For screening of an optimal RPA kit, four RPA assay kits were compared under 428 the same conditions, including Amp-Qitian kit (Qitian gene Biotech, Wuxi, China), 429 Amp-Future kit (Amp-Future, Weifang, China), TwistAmp Baic kit (TwistDx, 430 Cambridge, UK), and Amp-Yizhi Kit (Yizhi Biotech, Shenzhen, China). Briefly, 10 431 432 ul RT product was transferred into a 50 ul volume basic RPA reaction mixture using 433 these four kits, respectively, which contains 29.5 µl rehydration buffer, one freeze-dried RPA reaction pellet, 0.5 µM RT-RPA forward and reverse primer mix, 434 and 14 mM MgOAc (last added to initiate the reaction). The RPA reaction mixture 435 436 was incubated at 37 °C for 15 min. RNase-free water was used as the negative 437 control.

438

To investigate the possible effects of T4 gene 32 protein and Bsu DNA

439	polymerase on RPA reaction, basic RPA reaction mixture was prepared as described
440	above with or without the addition of 16.5 μM T4 gene 32 protein (Cat* M0300L,
441	New England Biolabs) or 0.25U Bsu DNA polymerase (Cat [#] M0330S, New England
442	Biolabs).
443	The RT-RPA products were analyzed by fluorescence based CRISPR assay as
444	described above. Finally, a 50 μ l volume-optimized RPA reaction mixture was
445	obtained as below: 29.5 µl rehydration buffer (TwistDx), one freeze-dried RPA
446	reaction pellet (TwistDx), 10 μ l RT product, 0.5 μ M RT-RPA forward and reverse
447	primer mix, 16.5 μ M T4 gene 32 protein (Cat [#] M0300L, New England Biolabs) and
448	14 mM MgOAc.
449	To determine if the CRISPR reaction has a higher efficiency using manganese
450	rather than magnesium, as described before(Li et al. 2020). The fluorescence-based
451	CRISPR assay was used to quantify the results as described above, with 10 mM
452	MnCl ₂ or MgCl ₂ in the basic CRISPR reaction mixture.
453	Furthermore, the optimal concentrations of FQ-ssDNA and FB-ssDNA probes
454	were determined within the basic CRISPR reaction mixture. The FQ-ssDNA probe
455	(10, 15, or 20 nM) and FB-ssDNA probe (0.5, 5, 25, 50, 125, 200, 500, 1000, or
456	2000 nM) were used in the CRISPR reaction, and the corresponding reaction
457	fluorescence intensities and lateral-flow readouts were recorded as described above,
458	respectively.
459	Finally, a 100 μ l volume-optimized CRISPR reaction mixture was obtained as
460	below: $1 \times Lba$ Cas12a buffer (Cat [#] M0653T, New England Biolabs), 5 µl RT-RPA
461	product, 0.2 µM LbaCas12a (Cat# M0653T, New England Biolabs), 0.6 µM crRNA,
462	10 μ M MgCl ₂ , and 20 nM FAM-BHQ1 ssDNA probe for the fluorescence-based
463	detection, or 200 nM FTIC-Biotin ssDNA probe for the lateral flow-based detection.

464

465 Comparison of the one-step and two-step RT-RPA

466	The amplification efficiency from the one-step and two-step RT-RPA was
467	compared by using E gene as the detection target. The two-step RT-RPA was
468	conducted using the optimized RT-RPA mixtures as described above, while the
469	one-step RT-RPA was performed by adding all the reaction reagents at once and
470	incubated at 37 °C for 30 min. The 50 μl -reaction mixture of the one-step RT-RPA
471	contains 29.5 μ l rehydration buffer, 10 μ l RNA template, one freeze-dried Twist RPA
472	reaction pellet, 2.5 μ M RT-RPA forward and reverse primer mix, 0.4 mM dNTP mix,
473	200 U RevertAid reverse transcriptase, 6.6 μ M T4 gene 32 protein, 100 U RNase H,
474	10 U RNase inhibitor, and 14 mM MgOAc. The RT-RPA products were loaded into
475	8% PAGE gel and the relative greyness of sample bands was quantified using
476	ImageJ.
477	
478	Validation of RRCd in detection and discrimination of clinical samples
479	To evaluate the performance of RRCd on SARS-CoV-2 clinical samples, a
480	
	total of 204 swabs were collected at SITHC from March 3 rd and to October 29 th 2021
481	total of 204 swabs were collected at SITHC from March 3 rd and to October 29 th 2021 and were used to perform the RRCd assay. Both lateral-flow and fluorescence-based
481 482	total of 204 swabs were collected at SITHC from March 3 rd and to October 29 th 2021 and were used to perform the RRCd assay. Both lateral-flow and fluorescence-based readouts were recorded. A total of 96 clinical samples were used to detect
481 482 483	 total of 204 swabs were collected at SITHC from March 3rd and to October 29th 2021 and were used to perform the RRCd assay. Both lateral-flow and fluorescence-based readouts were recorded. A total of 96 clinical samples were used to detect SARS-CoV-2 by targeting <i>E</i> gene and <i>S</i> gene, and a total of 108 clinical samples
481 482 483 484	 total of 204 swabs were collected at SITHC from March 3rd and to October 29th 2021 and were used to perform the RRCd assay. Both lateral-flow and fluorescence-based readouts were recorded. A total of 96 clinical samples were used to detect SARS-CoV-2 by targeting <i>E</i> gene and <i>S</i> gene, and a total of 108 clinical samples were used to detect and discriminate the SARS-CoV-2 VOCs by targeting <i>S</i> gene
 481 482 483 484 485 	 total of 204 swabs were collected at SITHC from March 3rd and to October 29th 2021 and were used to perform the RRCd assay. Both lateral-flow and fluorescence-based readouts were recorded. A total of 96 clinical samples were used to detect SARS-CoV-2 by targeting <i>E</i> gene and <i>S</i> gene, and a total of 108 clinical samples were used to detect and discriminate the SARS-CoV-2 VOCs by targeting <i>S</i> gene 501 or 478. The RRCd results were analyzed and compared with the results of
 481 482 483 484 485 486 	 total of 204 swabs were collected at SITHC from March 3rd and to October 29th 2021 and were used to perform the RRCd assay. Both lateral-flow and fluorescence-based readouts were recorded. A total of 96 clinical samples were used to detect SARS-CoV-2 by targeting <i>E</i> gene and <i>S</i> gene, and a total of 108 clinical samples were used to detect and discriminate the SARS-CoV-2 VOCs by targeting <i>S</i> gene 501 or 478. The RRCd results were analyzed and compared with the results of RT-qPCR and genome sequencing.

488 **RRCd using the directly released RNA**

489	Viral RNAs from SARS-CoV-2 pseudovirus and clinical samples were
490	released directly by a Sample release reagent kit (Sansure Biotech, Changsha, China)
491	according to the manufacturer's instructions with minor modifications. The swab
492	storage solution and the sample release reagent were mixed in a ratio of 1:1 and
493	incubated at 37 °C for 5 min before subsequent assays.
494	
495	Statistical analysis
496	Data were represented as mean \pm S.D. from three independent experiments
497	otherwise indicated. Statistical significances were analyzed by using the R (version
498	4.1.1). Unpaired one-tailed <i>t</i> -test was applied to investigate the differences between
499	groups assuming P value < 0.05 as significant.
500	
501	Acknowledgements
502	We are grateful to Prof. Xian-En Zhang for generously providing the
503	pseudovirus, and Prof. Hang Dai and Dr. Xiaonan Yang for constructive discussion on
504	this project. This study was supported by the National Key R&D Program of China
505	(2019YFA0904003, 2020YFA0909100), the Strategic Priority Research Program of
506	the Chinese Academy of Sciences, China (XDB38020300), the Guangdong Basic and
507	Applied Basic Research Foundation (2021A1515012511), and the General
508	Administration of Customs Project (2020HK003).
509	
510	Author contributions
511	G.P.Z., Z.G.T. and W.Z. conceived and designed the study. G.T., Z.Z., W.T.
512	and F.L. performed the experiments and analyzed data. All authors contributed to
513	writing and editing of the manuscript. W.Z. supervised the research.

515 Competing interests

- 516 G.Y.T., W.T., G.P.Z. and W.Z. are co-inventors on patent applications filed by
- 517 Shenzhen Institutes of Advanced Technology relating to the work in this manuscript.
- 518 The remaining authors declare no conflict of interest.
- 519

520 **References**

521 522 Broughton, J. P., X. Deng, G. Yu, C. L. Fasching, V. Servellita, J. Singh, X. Miao, J. A. Streithorst, A. 523 Granados, A. Sotomayor-Gonzalez, K. Zorn, A. Gopez, E. Hsu, W. Gu, S. Miller, C. Y. Pan, 524 H. Guevara, D. A. Wadford, J. S. Chen, and C. Y. Chiu. 2020. "CRISPR-Cas12-based detection of SARS-CoV-2." Nat Biotechnol 38 (7):870-874. doi: 525 526 10.1038/s41587-020-0513-4. 527 Buch, J., K. Roomp, G. Bach, L. Steinbruck, M. Beer, V. Gregory, N. Komadina, Y. Lan, I. Monne, C. Smith, S. Fujisaki, P. Bogner, and T. Lengauer. 2011. "GISAID - a global initiative on 528 529 sharing all influenza data." Influenza and Other Respiratory Viruses 5:419-419. 530 Chen, J. S., E. Ma, L. B. Harrington, M. Da Costa, X. Tian, J. M. Palefsky, and J. A. Doudna. 2018. 531 "CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity." 532 Science 360 (6387):436-439. doi: 10.1126/science.aar6245. Crits-Christoph, A., R. S. Kantor, M. R. Olm, O. N. Whitney, B. Al-Shayeb, Y. C. Lou, A. Flamholz, 533 534 L. C. Kennedy, H. Greenwald, A. Hinkle, J. Hetzel, S. Spitzer, J. Koble, A. Tan, F. Hyde, G. 535 Schroth, S. Kuersten, J. F. Banfield, and K. L. Nelson. 2021. "Genome Sequencing of 536 Sewage Detects Regionally Prevalent SARS-CoV-2 Variants." Mbio 12 (1). doi: ARTN 537 e02703-2010.1128/mBio.02703-20. 538 de Puig, H., R. A. Lee, D. Najjar, X. Tan, L. R. Soeknsen, N. M. Angenent-Mari, N. M. Donghia, N. E. 539 Weckman, A. Ory, C. F. Ng, P. Q. Nguyen, A. S. Mao, T. C. Ferrante, G. Lansberry, H. 540 Sallum, J. Niemi, and J. J. Collins. 2021. "Minimally instrumented SHERLOCK 541 (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging 542 variants." Sci Adv 7 (32). doi: 10.1126/sciadv.abh2944. 543 Ding, X., K. Yin, Z. Li, R. V. Lalla, E. Ballesteros, M. M. Sfeir, and C. Liu. 2020. "Ultrasensitive and 544 visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay." Nat 545 Commun 11 (1):4711. doi: 10.1038/s41467-020-18575-6. 546 Fozouni, P., S. Son, M. Diaz de Leon Derby, G. J. Knott, C. N. Gray, M. V. D'Ambrosio, C. Zhao, N. 547 A. Switz, G. R. Kumar, S. I. Stephens, D. Boehm, C. L. Tsou, J. Shu, A. Bhuiya, M. 548 Armstrong, A. R. Harris, P. Y. Chen, J. M. Osterloh, A. Meyer-Franke, B. Joehnk, K. Walcott, 549 A. Sil, C. Langelier, K. S. Pollard, E. D. Crawford, A. S. Puschnik, M. Phelps, A. Kistler, J. 550 L. DeRisi, J. A. Doudna, D. A. Fletcher, and M. Ott. 2021. "Amplification-free detection of 551 SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy." Cell 184 (2):323-333 552 e9. doi: 10.1016/j.cell.2020.12.001. 553 Hadfield, J., C. Megill, S. M. Bell, J. Huddleston, B. Potter, C. Callender, P. Sagulenko, T. Bedford,

1
-407
9407.
Sarreuo, A. Kanu, K. K.
\therefore Huang, X . G. Yu, J. Z.
Jootenberg, U. U.
SHERLOCK One-Pot
c2026172.
o Cano, Emily Haag, Jerry
ndersen, Chunlei Wu,
for Viral Systems Biology.
rthy, P. Kathpalia, A.
nd D. Chakraborty. 2021.
n of major SARS-CoV-2
Omicron and Delta variant
ein." J Med Virol 94
ong, Y. X. Shi, X. B. Ni, Y.
Cui, J. Li, G. Q. Pei, X.
. Leung, E. C. Holmes, Y.
elated coronaviruses in
1586-020-2169-0.
Dong. 2020.
Can Be Inactivated by
52. doi:
"CRISPR-Cas12a has
Cell Res 28 (4):491-493.
, G. P. Zhao, and J. Wang.
<i>scov</i> 4:20. doi:
LC Genomics
-0716-0223-2 4.
Scharton, C. Schindewolf,
The N501Y spike
Nature 602
fication: Basics.
fication: Basics, . doi:
fication: Basics, . doi:
fication: Basics, . doi: rvev. S. Lytras A

598	Consortium, L. M. Duncan, A. M. Carabelli, J. C. Kenyon, A. M. Lever, A. De Marco, C.
599	Saliba, K. Culap, E. Cameroni, N. J. Matheson, L. Piccoli, D. Corti, L. C. James, D. L.
600	Robertson, D. Bailey, and R. K. Gupta. 2021. "Recurrent emergence of SARS-CoV-2 spike
601	deletion H69/V70 and its role in the Alpha variant B.1.1.7." Cell Rep 35 (13):109292. doi:
602	10.1016/j.celrep.2021.109292.
603	Munnink, B. B. O., N. Worp, D. F. Nieuwenhuijse, R. S. Sikkema, B. Haagmans, R. A. M. Fouchier,
604	and M. Koopmans. 2021. "The next phase of SARS-CoV-2 surveillance: real-time molecular
605	epidemiology." Nature Medicine 27 (9):1518-1524. doi: 10.1038/s41591-021-01472-w.
606	Nyberg, T., N. M. Ferguson, S. G. Nash, H. H. Webster, S. Flaxman, N. Andrews, W. Hinsley, J. L.
607	Bernal, M. Kall, S. Bhatt, P. Blomquist, A. Zaidi, E. Volz, N. A. Aziz, K. Harman, S. Funk, S.
608	Abbott, Covid- Genomics UK consortium, R. Hope, A. Charlett, M. Chand, A. C. Ghani, S.
609	R. Seaman, G. Dabrera, D. De Angelis, A. M. Presanis, and S. Thelwall. 2022. "Comparative
610	analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron
611	(B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study." Lancet. doi:
612	10.1016/S0140-6736(22)00462-7.
613	Oude Munnink, B. B., N. Worp, D. F. Nieuwenhuijse, R. S. Sikkema, B. Haagmans, R. A. M.
614	Fouchier, and M. Koopmans. 2021. "The next phase of SARS-CoV-2 surveillance: real-time
615	molecular epidemiology." Nat Med 27 (9):1518-1524. doi: 10.1038/s41591-021-01472-w.
616	Patchsung, M., K. Jantarug, A. Pattama, K. Aphicho, S. Suraritdechachai, P. Meesawat, K. Sappakhaw,
617	N. Leelahakorn, T. Ruenkam, T. Wongsatit, N. Athipanyasilp, B. Eiamthong, B.
618	Lakkanasirorat, T. Phoodokmai, N. Niljianskul, D. Pakotiprapha, S. Chanarat, A. Homchan,
619	R. Tinikul, P. Kamutira, K. Phiwkaow, S. Soithongcharoen, C. Kantiwiriyawanitch, V.
620	Pongsupasa, D. Trisrivirat, J. Jaroensuk, T. Wongnate, S. Maenpuen, P. Chaiyen, S.
621	Kamnerdnakta, J. Swangsri, S. Chuthapisith, Y. Sirivatanauksorn, C. Chaimayo, R. Sutthent,
622	W. Kantakamalakul, J. Joung, A. Ladha, X. Jin, J. S. Gootenberg, O. O. Abudayyeh, F.
623	Zhang, N. Horthongkham, and C. Uttamapinant. 2020. "Clinical validation of a Cas13-based
624	assay for the detection of SARS-CoV-2 RNA." Nat Biomed Eng 4 (12):1140-1149. doi:
625	10.1038/s41551-020-00603-x.
626	Peto, T., and Uk Covid- Lateral Flow Oversight Team. 2021. "COVID-19: Rapid antigen detection for
627	SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and
628	specificity for mass-testing." EClinicalMedicine 36:100924. doi:
629	10.1016/j.eclinm.2021.100924.
630	Piepenburg, O., C. H. Williams, D. L. Stemple, and N. A. Armes. 2006. "DNA detection using
631	recombination proteins." Plos Biology 4 (7):1115-1121. doi: ARTN
632	e20410.1371/journal.pbio.0040204.
633	Qian, J., S. A. Boswell, C. Chidley, Z. X. Lu, M. E. Pettit, B. L. Gaudio, J. M. Fajnzylber, R. T.
634	Ingram, R. H. Ward, J. Z. Li, and M. Springer. 2020. "An enhanced isothermal amplification
635	assay for viral detection." Nat Commun 11 (1):5920. doi: 10.1038/s41467-020-19258-y.
636	Tao, K., P. L. Tzou, J. Nouhin, R. K. Gupta, T. de Oliveira, S. L. Kosakovsky Pond, D. Fera, and R. W.
637	Shafer. 2021. "The biological and clinical significance of emerging SARS-CoV-2 variants."
638	Nat Rev Genet 22 (12):757-773. doi: 10.1038/s41576-021-00408-x.
639	Tegally, H., E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, D. Doolabh, S.
640	Pillay, E. J. San, N. Msomi, K. Mlisana, A. von Gottberg, S. Walaza, M. Allam, A. Ismail, T.
641	Mohale, A. J. Glass, S. Engelbrecht, G. Van Zyl, W. Preiser, F. Petruccione, A. Sigal, D.

642	Hardie, G. Marais, N. Y. Hsiao, S. Korsman, M. A. Davies, L. Tyers, I. Mudau, D. York, C.
643	Maslo, D. Goedhals, S. Abrahams, O. Laguda-Akingba, A. Alisoltani-Dehkordi, A. Godzik,
644	C. K. Wibmer, B. T. Sewell, J. Lourenco, L. C. J. Alcantara, S. L. Kosakovsky Pond, S.
645	Weaver, D. Martin, R. J. Lessells, J. N. Bhiman, C. Williamson, and T. de Oliveira. 2021.
646	"Detection of a SARS-CoV-2 variant of concern in South Africa." Nature 592
647	(7854):438-443. doi: 10.1038/s41586-021-03402-9.
648	Teng, F., L. Guo, T. Cui, X. G. Wang, K. Xu, Q. Gao, Q. Zhou, and W. Li. 2019. "CDetection:
649	CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base
650	specificity." Genome Biol 20 (1):132. doi: 10.1186/s13059-019-1742-z.
651	Villalva, C., C. Touriol, P. Seurat, P. Trempat, G. Delsol, and P. Brousset. 2001. "Increased yield of
652	PCR products by addition of T4 gene 32 protein to the SMART PCR cDNA synthesis
653	system." Biotechniques 31 (1):81-3, 86. doi: 10.2144/01311st04.
654	Vogels, C. B. F., M. I. Breban, I. M. Ott, T. Alpert, M. E. Petrone, A. E. Watkins, C. C. Kalinich, R.
655	Earnest, J. E. Rothman, J. G. de Jesus, I. M. Claro, G. M. Ferreira, M. A. E. Crispim, L.
656	Singh, H. Tegally, U. J. Anyaneji, E. B. Hodcroft, C. E. Mason, G. Khullar, J. Metti, J. T.
657	Dudley, M. J. MacKay, M. Nash, J. H. Wang, C. Liu, P. Hui, S. Murphy, C. Neal, E. Laszlo,
658	M. L. Landry, A. Muyombwe, R. Downing, J. Razeq, T. de Oliveira, N. R. Faria, E. C.
659	Sabino, R. A. Neher, J. R. Fauver, N. D. Grubaugh, Brazil-UK CADDE Genomic Network,
660	and Network Genomic Surveillance South. 2021. "Multiplex qPCR discriminates variants of
661	concern to enhance global surveillance of SARS-CoV-2." Plos Biology 19 (5). doi: ARTN
662	e300123610.1371/journal.pbio.3001236.
663	Wang, Y., Y. Zhang, J. Chen, M. Wang, T. Zhang, W. Luo, Y. Li, Y. Wu, B. Zeng, K. Zhang, R. Deng,
664	and W. Li. 2021. "Detection of SARS-CoV-2 and Its Mutated Variants via
665	CRISPR-Cas13-Based Transcription Amplification." Anal Chem 93 (7):3393-3402. doi:
666	10.1021/acs.analchem.0c04303.
667	

668 Table 1. Comparison of RRCd with DETECTR and SHERLOCK for the

	RRCd	DETECTR (Broughton et al. 2020)	SHERLOCK (Patchsung et al. 2020)
Target genes	S, E and N	E and N	Orflab, S and N
Assay procedures	RT-RPA (37 °C, 30 min); Cas12 reaction (37 °C, 30 min); Lateral flow strip (room temperature, 2 min)	RT-LAMP (62 °C, 20-30 min); Cas12 reaction (37 °C, 10 min); Lateral flow strip (room temperature, 2 min)	RT-RPA (42 °C, 25 min); T7 transcription and Cas13 reaction (37 °C, 30 min); Lateral flow strip (room temperature, 2 min)
Assay time	~ 60 min	~ 45 min	~ 60 min
LoD	10	20	42
Specificity	SNP and small deletion	NA	NA
RNA purification dependence	No	Yes	Yes

669 SARS-CoV-2 detection.

670 LoD, limit of detection (copies per reaction); NA, not applicable.

	DDCd mogults	RT-qPCR-verified positive samples		RT-qPCR-verified
	KKCu results	$C_{\rm t}$ < 33	$C_{\rm t} \ge 33$	negative samples
ase	Positive	84 (true positive)	24 (true positive)	0 (false positive)
ce-b: out	Negative	1 (false negative)	13 (false negative)	82 (true negative)
scene	Total	85	37	82
iores d r	PPA/NPA	99%	65%	100%
FIL	Total PPA/NPA	8	9%	100%
	Positive	84 (true positive)	23 (true positive)	0 (false positive)
flow ut	Negative	1 (false negative)	14 (false negative)	82 (true negative)
eral- ado	Total	85	37	82
Late	PPA/NPA	99%	62%	100%
	Total PPA/NPA	8	8%	100%

Table 2. Predictive agreements of RRCd in detection of clinical samples.

In total, 204 clinical samples including 122 positive samples and 82 negative
 samples were analyzed by RRCd with both fluorescence-based and lateral-flow

readouts. PPA, positive predictive agreement; NPA, negative predictive agreement.



675

676 Figure 1. Detection and discrimination of SARS-CoV-2 VOCs by RRCd.

Schematic overview of RRCd workflow. (I) SARS-CoV-2 samples were released by 677 automatic extraction (~10 min) or using RNA release chemical agents without 678 extraction (~5 min). (II) The viral RNA was reverse transcribed into the dsDNA and 679 amplified by RPA. (III) Cas12a was guided to target the dsDNA by the specific 680 crRNA, thereby activated its *trans*-cleavage activity to the ssDNA probes in the 681 system. The results could be quantified by fluorescence detection of the cleaved 682 FQ-ssDNA (III a), or visualized by lateral-flow strip using the FB-ssDNA probe (III 683 b). RRCd in discrimination of SARS-CoV-2 VOCs with lateral-flow readout is 684 highlighted on the right panel. The target gene from SARS-CoV-2 variant was shown 685 as the template, and it was detected by either crRNA-VOC or crRNA-WT, leading to 686 the positive (upper right panel) or negative (lower right panel) test result, 687 respectively. dsDNA, double-strand DNA; ssDNA, single-strand DNA; FQ, 688 fluorophore (FAM)-quencher (BHQ1); FB, FITC-Biotin; PAM, protospacer adjacent 689 motif; VOC, variant of concern; WT, wild type; GNP, gold nanoparticle; gt, goat. 690



691

692 Figure 2. The specificity of RRCd in detection of SARS-CoV-2 VOCs. A.

Representative changes of amino acids in the spike protein in different SARS-CoV-2
VOCs. Data came from Outbreak.info (https://outbreak.info/compare-lineages) (Julia
L. Mullen 2021). The variations detected in this study are colored in red. A simple
model is shown on the right panel. Del, deletion. **B**. Specificity analysis of RRCd in

697	detection of SARS-CoV-2 S gene 501, using fluorescence-based readouts. The
698	dsDNA derived from pseudovirus S gene N501 or Y501 was incubated with Cas12a,
699	FQ-ssDNA, and distinct crRNA at 37 °C, and the corresponding fluorescence signal
700	was recorded over 60 min (left panel) and quantified at 30 min (right panel). Data are
701	presented as the mean \pm S.D. (n = 3). ***, $P < 0.01$ by student's <i>t</i> test. RNase-free
702	water was used as the negative control (NC). RFU, relative fluorescence units. C.
703	Specificity analysis of RRCd using lateral-flow readouts. The samples analyzed were
704	the same as those in panel B. The reactions were conducted at 37 $^{\circ}$ C for 30 min before
705	the mixtures were transferred onto the strips, using FB-ssDNA probe instead of
706	FQ-ssDNA. The relative greyness (G) of strip bands was quantified using ImageJ. In
707	this study, G_{Sample} / G_{NC} of the T band ≥ 1.5 indicates positive. D , E . Specificity
708	analysis of RRCd in detection of SARS-CoV-2 S gene 478. F, G. Specificity analysis
709	of RRCd in detection of SARS-CoV-2 S gene 69-70. H. Schematic of RRCd in
710	detection of SARS-CoV-2 VOCs by Cas12a cis-cleavage activity. I, J. The specificity
711	was demonstrated by PAGE analyses, using SARS-CoV-2 variants of N501Y and
712	Δ H69-V70 as the examples.



713

Figure 3. The detection limit of RRCd for SARS-CoV-2 VOCs. The detection limit of the targeted regions in VOCs were determined by using 10⁷, 10⁶, 10⁵, 10⁴, 10³, 10², 10 and 5 copies of pseudovirus RNA per reaction, respectively. The dsDNA derived from the pseudovirus RNA was incubated with Cas12a, ssDNA probe, and crRNA at 37 °C for 60 min (fluorescence-based readouts) or 30 min (lateral-flow readouts),

719 respectively. The relative fluorescence intensity (F/F ₀) was calculated as

- fluorescence signal versus the starting signal (left panel). Correspondingly, the
- fluorescence signal at the 30 min-reaction was quantified (middle panel). The positive
- samples of lateral-flow readouts (right panel) are indicated as blue by the T-line
- quantification as described. Data are presented as mean \pm S.D. from at least three
- independent experiments. For the dilutions with 10 and 5 copies per reaction, at least
- five independent experiments were conducted. A. LoD determination of RRCd for E
- 726 gene. **B-E**. LoD determinations of RRCd for N501 (B), Y501 (C), T478 (D) and K478
- 727 (E) in *S* gene, respectively. NC, negative control using the RNase-free water.





- 741 double-checked positive result. The white indicates the negative result. Only the
- 742 lateral-flow results of *E* gene are shown. +, positive; , negative or indistinguishable.
- The analyses of the detection results are shown as the number of false negatives and
- the false-negative rate for each C_t range on the bottom of the panel. The SARS-CoV-2
- 745 pseudovirus was used as the positive control. The full dataset is shown in
- 746 Supplementary Figure 9.



747

False

discriminant rate

Figure 5. Validation of RRCd in detection and discrimination of 108 748

0%

genome-sequencing-verified clinical samples. A. Discrimination of SARS-CoV-2 S 749

0%

0%

0%

0%

gene 501 variants in clinical samples. The total number of clinical samples in each $C_{\rm t}$ 750

- 751 range are shown on the top of the panel. In total, 47 positive samples (C_t range of
- 13-35) and 21 negative samples were detected. The S gene 501 variants were 752

753	discriminated by crRNA-N501 (green) and crRNA-Y501 (light blue) using
754	fluorescence-based readouts. In addition, the lateral-flow readouts are displayed in
755	the middle of the panel using crRNA-N501 (left) and crRNA-Y501 (right). N, N501;
756	Y, Y501; -, negative or indistinguishable. The analysis results are shown as the
757	number of false discriminants and the false-discriminant rate for each C_t range on the
758	bottom of the panel. B . Discrimination of SARS-CoV-2 S gene 478 variants in
759	clinical samples. In total, 21 positive samples (C_t range of 17-34) and 19 negative
760	samples were detected. The S gene 478 variants were discriminated by crRNA-T478
761	(blue) and crRNA-K478 (pink) by fluorescence readouts. The lateral-flow readouts
762	using crRNA_T478 (left) and crRNA_K478 (right) are displayed on the below. T,
763	T478; K, K478; -, negative or indistinguishable. The corresponding SARS-CoV-2
764	pseudoviruses were used as the positive controls. The full datasets for panel a and b
765	are shown in Supplementary Figure 10 and Supplementary Figure 11, respectively.